Evidence map›Paper›PMID 35718707›Full record

ArticleTrends in cancer2022

Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi.

Katerina Grafanaki, Glenn Merlino, Chi-Ping Day

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Katerina GrafanakiLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Dermatology, University Hospital of Patras, School of Medicine, University of Patras, Patras, Greece.
Glenn MerlinoLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Chi-Ping DayLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: chi-ping.day@nih.gov.
National Institutes of Health · US

Funding

Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor ResponseZIABC011167 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MERLINO, GLENN T. · 2009 to 2024
$12.4M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Patients with congenital giant nevi (CGN), which can compromise quality of life and progress to melanoma, have limited treatment options. Choi et al. have demonstrated that topical application of a proinflammatory hapten for alopecia treatment [squaric acid dibutylester (SADBE)] caused nevus regression and prevented melanoma in an Nras mouse CGN model. Their results demonstrate the promise of repurposing drugs through precision modeling.

Indexed as

Alopecia AreataMelanomaNevus, PigmentedHumansQuality of LifeSkin Neoplasmscongenital giant nevi (CGN)drug repurposinggenetically engineered mice (GEM)M1 macrophagesNrassquaric acid dibutylester (SADBE)

Identifiers

PMID35718707
PMCPMC9308749
OpenAlexW4283066190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.